The New Zealand sharemarket ended a strong week with a gain of more than 1.8%, erasing the year’s earlier losses, and powered ...

Fisher and Paykel Healthcare hit a record high and led the New Zealand sharemarket to a small gain, while Wall St kept ...

US tariffs could mean a $46 million hit to Fisher & Paykel Healthcare’s profit in a worst-case scenario, analysts say. A ...

Goldman Sachs analyst Davin Thillainathan initiated coverage of Fisher & Paykel Healthcare with a Buy rating and A$42.70 price target The ...

Find insight on Novartis, Masimo, Fisher & Paykel and more in the latest Market Talks covering Health Care.

Medical device maker Fisher & Paykel Healthcare faces a significant impact from potential tariffs in the US, say research ...

The New Zealand sharemarket, dictated by the volatile Fisher and Paykel Healthcare stock, posted another small decline and ...

Trump’s proposed 25% tariffs on Mexico and Canada could disrupt healthcare companies, particularly those manufacturing in ...

Initial US respiratory data indicates Fisher & Paykel Healthcare (FPH) is likely to reach the top end of its guidance of ...

Goldman Sachs began coverage on Fisher & Paykel Healthcare (FPH:AU) (OTC: FSPKF), issuing a Buy rating and setting a price target of NZD42.70. The firm's positive stance on the healthcare company is ...

New Zealand-listed shares have underperformed compared to many global markets with greater exposure to tech sector gains, ...

The sensitive information stored in health systems, coupled with inadequate security measures, makes the healthcare infrastructure appealing to cybercriminals.